

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 54192

**Title:** Rare case of primary cutaneous mantle cell lymphoma: A case report

**Reviewer's code:** 00058381

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** Austria

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-01-18

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-01-18 16:24

**Reviewer performed review:** 2020-01-19 12:40

**Review time:** 20 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

A clinical description of a patient with primary cutaneous mantle cell lymphoma is presented, including illustrative pictures. This manuscript does not break new ground, but the authors provide an overview of the literature published on this subject. The references require thorough revision; the citation numbers in the text and in the reference list are not consistent; e.g., Discussion, third paragraph: "Wehkamp et al. [7]", but in the reference list number 7 is "Gru et al." ("Wehkamp et al." is number 6); Table 1: "Esthozi et al. [10]", but in the reference list number 10 is "Zattra et al.", etc. Moreover, there is also incorrect spelling ("Esthozi" -> Estrozi). Case summary: "through out" -> throughout; "to mography" -> tomography. Section "Laboratory examinations", second paragraph: "featureof" -> feature of. Section "Imaging examinations": "tomographydid" -> tomography did. Discussion, first paragraph: "controversial. it is not included" -> controversial. It is not included. Discussion, second paragraph: "Senet" -> Sen et; "Wehkampet"-> Wehkamp et. Discussion, third paragraph: "...found that all of their analyzed cases,except two, had blastic features, which was are considered extensively aggressive" - please correct this sentence; "byWehkampet" -> by Wehkamp et; "whichdid" -> which did. Discussion, last paragraph: "whereasthe" -> whereas the; "theskin lesions" -> the skin lesions. Conclusion: "Correctdiagnosis" -> Correct diagnosis. Some spaces are also missing in the tables, in the figure legends and in the reference list.

## INITIAL REVIEW OF THE MANUSCRIPT

### *Google Search:*

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**<https://www.wjgnet.com>**

***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 54192

**Title:** Rare case of primary cutaneous mantle cell lymphoma: A case report

**Reviewer's code:** 02536364

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-01-18

**Reviewer chosen by:** Ruo-Yu Ma

**Reviewer accepted review:** 2020-02-18 10:06

**Reviewer performed review:** 2020-02-19 00:01

**Review time:** 13 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

In 2016 revised edition of the WHO classification, in the mantle cell lymphoma (MCL), 'in situ MCL' and 'non-nodal, leukemic MCL' were subclassified. Well, this paper is a case report of primary cutaneous MCL. This is a very rare condition, and the accumulation of such cases may lead to a new revision of the WHO classification in the future. This paper is a very important report, and the patient's presentation was indeed essential. In discussions, it was clearly explained that primary cutaneous MCL has completely different biological activity from MCL that involved into the skin. Apparently, primary cutaneous MCL belongs to indolent lymphoma, and its treatment seems to be different from classic MCL. This time, please describe the chemotherapy regimen for Case 3 and Case 5 (unknown if you do not know) in the listed review (Table 1). I don't think there is anything else to add, change or delete.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

##### ***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No